TENX (Tenax Therapeutics) Stock Based Compensation: $17.86 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TENX Tenax Therapeutics Inc TENX
22 GF Score
Price $15.56
! 2 Warning Signs
View Full Analysis

What is Tenax Therapeutics Stock Based Compensation?

Tenax Therapeutics TENX -2.63% 22 Stock Based Compensation is $17.86 Mil as of Mar. 2026. GuruFocus rates TENX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Tenax Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was $2.84 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $17.86 Mil.

Tenax Therapeutics Stock Based Compensation Related Terms

Tenax Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Tenax Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenax Therapeutics Stock Based Compensation Chart

Tenax Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.19 1.13 19.16

Tenax Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.14 4.61 5.62 4.79 2.84
TENX
22GF Score
Tenax Therapeutics Inc TENX
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tenax Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.86 Mil.

What does a Stock Based Compensation of $17.86 Mil mean?
Tenax Therapeutics (TENX) has a Stock Based Compensation of $17.86 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Tenax Therapeutics and its competitors.
Is Tenax Therapeutics' Stock Based Compensation too high?
Tenax Therapeutics' current Stock Based Compensation is $17.86 Mil. Overall, Tenax Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Tenax Therapeutics' Stock Based Compensation compare to RCKT and AVIR?
Tenax Therapeutics' Stock Based Compensation of $17.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Tenax Therapeutics and its competitors. Tenax Therapeutics's current Stock Based Compensation is $17.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenax Therapeutics stock overvalued right now?
Tenax Therapeutics (TENX) has a current Stock Based Compensation of $17.86 Mil. The current Stock Based Compensation is $17.86 Mil. Tenax Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Tenax Therapeutics (TENX), the current Stock Based Compensation is $17.86 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tenax Therapeutics Business Description

Other Exchanges YBO0:Germany
Address 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
22GF Score

Get the complete analysis for TENX

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.56
Price